The identification of 25-hydroxyvitamin D3 as the primary circulating form of vitamin D serves as a foundational milestone in modern endocrinology. Michael F. Holick, a physician and biochemist, translated this discovery into global clinical practice, establishing the diagnostic standard for measuring patient vitamin D status and determining how cutaneous synthesis relies on solar exposure.
Academic and Research Foundations
Holick completed his Ph.D. in biochemistry and his medical degree at the University of Wisconsin–Madison. Following a postdoctoral fellowship, he moved to Massachusetts General Hospital for his medical residency. Since 1978, he has operated as a practitioner of adult and pediatric endocrinology. At Boston University Medical Center, he served as professor of medicine, physiology, and biophysics, while directing both the Bone Health Care Clinic and the Heliotherapy, Light, and Skin Research Center.
Twenty questions, eight minutes on the clock, and a percentile measured against everyone who has taken it. No sign-up.
Take the IQ test →Contributions to Vitamin D Science
His research portfolio includes over 400 publications detailing vitamin D metabolism. Beyond identifying 25-hydroxyvitamin D3, he participated in the chemical synthesis of 1,25-dihydroxyvitamin D3 and 1α-hydroxyvitamin D3 to address conditions like renal osteodystrophy and hypoparathyroidism. Holick mapped the inhibitory effects of active vitamin D on keratinocyte proliferation, leading to its topical application for psoriasis treatment. He also established that obesity-related deficiency often results from sequestration in fat tissue and confirmed that vitamin D remains bioavailable when fortified in orange juice.
Professional Appointments and Reviews
Holick has held significant advisory and editorial roles, including his position as chair of the Endocrine Practice Guidelines Committee for Vitamin D and chair of NASA's Human Health Countermeasures Element Standing Review Panel. He currently serves as editor-in-chief of the medical journal Clinical Laboratory. His scientific work has been widely cited across various media outlets, including Time, Forbes, and The New York Times, reflecting the influence of his clinical investigations.
Medical Controversies and Discipline
His career has faced notable scrutiny regarding his advocacy for sun exposure, which involved funding from a tanning bed company and subsequent criticism from peers at Boston University. Furthermore, Holick has faced professional repercussions for providing expert testimony linking Ehlers–Danlos syndrome to non-traumatic fractures in infants, a stance contested by other physicians. Following reports of health care facility discipline, Boston Medical Center barred him from treating patients in 2017. He has also been a recipient of substantial payments from pharmaceutical companies, including Sanofi-Aventis and Amgen, according to the Medicare Open Payments database.
Fast facts
- Born: 1946
- Citizenship: United States
- Alma Mater: University of Wisconsin–Madison
- Employer: Boston University
- Award: Prize for Health Research (2009)
- Professional Field: Endocrinology
Questions readers ask
What is Michael F. Holick's current status at Boston Medical Center?
Since May 2017, he is forbidden from evaluating or treating patients at the facility, though he may continue evaluating children involved in his specific research projects.
Which major vitamin D metabolite did he identify?
He identified 25-hydroxyvitamin D3, which is the standard metabolite measured by physicians worldwide to determine a patient's vitamin D status.
Achievements
- Prize for Health Research — 2009
- Held posts at Boston University
- Fields: vitamin D
.jpg)
